KRAS and neoplasm: Similar to that observed in the in vitro study, expression of CA-KRAS reversed the reduction in TAZ protein levels resulting from ICMT knockdown, as assessed by tumor sample immunoblot (Fig. 5e) and immunohistochemistry analysis of the tumor tissue (Fig. 5f).